Importantly, as anti-TWEAK therapy has proven useful in preclinical models of autoimmune diseases, and as lower serum levels of TWEAK are associated with better outcomes, it is possible that TWEAK may also represent a viable therapeutic target in COVID-19 and similar infections. Here, TNFSF12 is linked to autoimmune disease.